Kymera Therapeutics, Inc.
KYMRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by. Valued at $9.21B, KYMR is a mid-cap name in its sector. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Market Cap
$9.21B
Beta
1.98
P/E (TTM)
—
P/E (Fwd)
-21.73
EPS (TTM)
$-3.24
EPS (Fwd)
$-5.10
ROE
-24.1%
ROA
-15.6%
Cash
$691.0M
Total Debt
$78.6M
Free CF
-$144.1M
52W Change
89.1%
Annual Financials
Cash vs Debt
Where KYMR stands vs its 150-day and 200-day moving averages
As of the September 28, 2026 close, KYMR finished 15.27% above its 150-day moving average ($97.12) and 21.07% above its 200-day moving average ($92.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYMR overbought or oversold?
At the September 28, 2026 close, KYMR's RSI(14) was 40.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kymera Therapeutics, Inc. holds $691.0M in cash against $78.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$144.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -24.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $46.8M (2022) to $39.2M (2025), a 16% decline worth watching.
Kymera Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, KYMR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KYMR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.